Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study

Parkinson plus diseases, comprising mainly progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) are rare neurodegenerative conditions. We designed a double-blind randomized placebo-controlled trial of riluzole as a potential disease-modifying agent in Parkinson plus disorders (NNIP...

Descripción completa

Detalles Bibliográficos
Autores principales: Bensimon, Gilbert, Ludolph, Albert, Agid, Yves, Vidailhet, Marie, Payan, Christine, Leigh, P. Nigel
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2009
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2638696/
https://www.ncbi.nlm.nih.gov/pubmed/19029129
http://dx.doi.org/10.1093/brain/awn291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2638696/
https://www.ncbi.nlm.nih.gov/pubmed/19029129
http://dx.doi.org/10.1093/brain/awn291

Ejemplares similares